On April 27, 2022, the Competition Bureau announced that it has reached a settlement agreement with NuvoCare Health Sciences Inc and its founder (collectively “NuvoCare”), who were found to have made marketing claims that gave a false or misleading impression about their weight loss products.
Under paragraph 74.01(1)(b) of the Competition Act, a person cannot make a claim about a product’s performance, efficacy or length of life unless the claim is based on an adequate and proper test. The Competition Bureau’s investigation concluded that NuvoCare’s weight loss claims were not supported by adequate and proper testing.
As part of the settlement, NuvoCare agreed to pay $100,000 in penalties, change/remove all weight loss claims made about their products, and establish a corporate compliance program to prevent future deceptive marketing issues.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
Related Publications & Articles
-
Health Canada consultation on revised biosimilar guidance: no requirement for comparative clinical efficacy and safety trials
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More